

**Clinical trial results:****A Phase III Prospective, Two-Cohort Non-Randomized, Multi-Centre, Multinational, Open-Label Study to Assess the Safety of Assisted- and Self-Administered Subcutaneous Trastuzumab as Therapy in Patients With Operable HER2-Positive Early Breast Cancer (SafeHER)****Summary**

EudraCT number	2011-005328-17
Trial protocol	IE CZ DE ES FR HU PT GB NO IT GR LT PL SI SK FI BG NL SE
Global end of trial date	19 February 2020

**Results information**

Result version number	v2 (current)
This version publication date	04 March 2021
First version publication date	22 March 2017
Version creation reason	

**Trial information****Trial identification**

Sponsor protocol code	MO28048
-----------------------	---------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01566721
WHO universal trial number (UTN)	-

Notes:

**Sponsors**

Sponsor organisation name	F. Hoffmann- La Roche AG
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, CH-4070
Public contact	Roche Trial Information Hotline, F. Hoffmann-La Roche AG, +41 61 6878333, global.trial_information@roche.com
Scientific contact	Roche Trial Information Hotline, F. Hoffmann-La Roche AG, +41 61 6878333, global.trial_information@roche.com

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	29 June 2020
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	19 February 2020
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

This multicenter, two-cohort, non-randomized, open-label study is designed to evaluate the safety and tolerability of assisted and self-administered subcutaneous (SC) Herceptin (trastuzumab) as adjuvant therapy in subjects with early human epidermal growth factor receptor 2 (HER2)-positive breast cancer following tumor excision.

Protection of trial subjects:

The study was conducted in accordance with the principles of the "Declaration of Helsinki" and Good Clinical Practice (GCP) guidelines according to the regulations and procedures described in the protocol.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	16 May 2012
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	6 Years
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Albania: 8
Country: Number of subjects enrolled	Algeria: 16
Country: Number of subjects enrolled	Argentina: 13
Country: Number of subjects enrolled	Australia: 54
Country: Number of subjects enrolled	Bosnia and Herzegovina: 5
Country: Number of subjects enrolled	Brazil: 31
Country: Number of subjects enrolled	Bulgaria: 16
Country: Number of subjects enrolled	Canada: 50
Country: Number of subjects enrolled	Chile: 25
Country: Number of subjects enrolled	Colombia: 6
Country: Number of subjects enrolled	Croatia: 7
Country: Number of subjects enrolled	Czechia: 68
Country: Number of subjects enrolled	Dominican Republic: 2
Country: Number of subjects enrolled	Ecuador: 13
Country: Number of subjects enrolled	Egypt: 34
Country: Number of subjects enrolled	El Salvador: 6
Country: Number of subjects enrolled	France: 224

Country: Number of subjects enrolled	Germany: 235
Country: Number of subjects enrolled	Greece: 64
Country: Number of subjects enrolled	Guatemala: 16
Country: Number of subjects enrolled	Hong Kong: 10
Country: Number of subjects enrolled	Hungary: 39
Country: Number of subjects enrolled	Indonesia: 61
Country: Number of subjects enrolled	Ireland: 26
Country: Number of subjects enrolled	Italy: 203
Country: Number of subjects enrolled	Korea, Republic of: 59
Country: Number of subjects enrolled	Lithuania: 12
Country: Number of subjects enrolled	Malaysia: 45
Country: Number of subjects enrolled	Mexico: 52
Country: Number of subjects enrolled	Morocco: 8
Country: Number of subjects enrolled	Netherlands: 81
Country: Number of subjects enrolled	New Zealand: 10
Country: Number of subjects enrolled	Norway: 29
Country: Number of subjects enrolled	Pakistan: 46
Country: Number of subjects enrolled	Panama: 8
Country: Number of subjects enrolled	Peru: 26
Country: Number of subjects enrolled	Philippines: 48
Country: Number of subjects enrolled	Poland: 48
Country: Number of subjects enrolled	Portugal: 26
Country: Number of subjects enrolled	Romania: 43
Country: Number of subjects enrolled	Russian Federation: 82
Country: Number of subjects enrolled	Saudi Arabia: 3
Country: Number of subjects enrolled	Serbia: 23
Country: Number of subjects enrolled	Singapore: 8
Country: Number of subjects enrolled	Slovakia: 19
Country: Number of subjects enrolled	Slovenia: 5
Country: Number of subjects enrolled	South Africa: 17
Country: Number of subjects enrolled	Spain: 161
Country: Number of subjects enrolled	Sweden: 15
Country: Number of subjects enrolled	Switzerland: 40
Country: Number of subjects enrolled	Taiwan: 32
Country: Number of subjects enrolled	Thailand: 28
Country: Number of subjects enrolled	Turkey: 47
Country: Number of subjects enrolled	Ukraine: 17
Country: Number of subjects enrolled	United Arab Emirates: 5
Country: Number of subjects enrolled	United Kingdom: 283
Country: Number of subjects enrolled	Uruguay: 3
Country: Number of subjects enrolled	Venezuela, Bolivarian Republic of: 5
Country: Number of subjects enrolled	Vietnam: 11
Worldwide total number of subjects	2577
EEA total number of subjects	1321

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	2090
From 65 to 84 years	483
85 years and over	4

## Subject disposition

### Recruitment

Recruitment details:

In this international study, 2577 subjects were enrolled at 49 academic centers throughout North America, Europe, the Middle East, and South America.

### Pre-assignment

Screening details:

Of the 2984 subjects screened, a total of 2577 subjects were enrolled into the trial, and 2573 subjects received at least one dose of study treatment.

4 Subjects were not included in the Safety Follow-Up (SFU) ITT due to the lack of Principal Investigator signatures.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

From Baseline to Safety Follow-up Period (Up to 6 Years)

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Cohort A: SC Herceptin by Needle/Syringe

Arm description:

Subjects received SC Herceptin by an assisted administration as 600 milligrams (mg) every 3 weeks for a total of 18 doses/cycles. Each dose of SC Herceptin was taken from a single-use vial and injected by needle/syringe.

Arm type	Experimental
Investigational medicinal product name	Herceptin
Investigational medicinal product code	
Other name	Trastuzumab
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Herceptin was given as 600 mg SC (into thigh) on Day 1 of each 3-week cycle for up to 18 cycles. Safety Follow-up Period up to approximately 6 years.

<b>Arm title</b>	Cohort B: SC Herceptin by Single-Use Injection Device (SID)
------------------	---

Arm description:

Subjects received SC Herceptin as 600 mg every 3 weeks for a total of 18 doses/cycles. Each dose of SC Herceptin was administered from a pre-filled SID. The first administration was performed by a healthcare professional (HCP). Subsequent doses were self-administered by subjects who were willing and judged competent by the HCP.

Arm type	Experimental
Investigational medicinal product name	Herceptin
Investigational medicinal product code	
Other name	Trastuzumab
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Herceptin was given as 600 mg SC (into thigh) on Day 1 of each 3-week cycle for up to 18 cycles. Safety Follow-up Period, up to approximately 6 years.

Number of subjects in period 1	Cohort A: SC Herceptin by Needle/Syringe	Cohort B: SC Herceptin by Single- Use Injection Device (SID)
Started	1867	710
Completed Treatment (ITT)	1670	652
Started Safety Follow-up (ITT)	1865	708
Completed	1318	501
Not completed	549	209
Physician decision	6	4
Disease progression /disease recurrence	223	90
Erroneous reporting or late reporting	2	-
Sponsor decision	1	-
Missing	7	2
Site closure	2	3
Consent withdrawn by subject	155	49
Adverse event, non-fatal	8	4
Death	28	4
Non-compliance	7	3
Lost to follow-up	101	48
Investigator signature missing	2	2
Protocol deviation	7	-

## Baseline characteristics

### Reporting groups

Reporting group title	Cohort A: SC Herceptin by Needle/Syringe
Reporting group description: Subjects received SC Herceptin by an assisted administration as 600 milligrams (mg) every 3 weeks for a total of 18 doses/cycles. Each dose of SC Herceptin was taken from a single-use vial and injected by needle/syringe.	
Reporting group title	Cohort B: SC Herceptin by Single-Use Injection Device (SID)
Reporting group description: Subjects received SC Herceptin as 600 mg every 3 weeks for a total of 18 doses/cycles. Each dose of SC Herceptin was administered from a pre-filled SID. The first administration was performed by a healthcare professional (HCP). Subsequent doses were self-administered by subjects who were willing and judged competent by the HCP.	

Reporting group values	Cohort A: SC Herceptin by Needle/Syringe	Cohort B: SC Herceptin by Single-Use Injection Device (SID)	Total
Number of subjects	1867	710	2577
Age categorical			
From total 2577 subjects, 4 subjects did not receive the study treatment, therefore 2573 subjects were included Baseline Characteristics.			
Units: Years			
Age continuous			
Units: years			
arithmetic mean	54	53	
standard deviation	± 12.01	± 11.32	-
Gender categorical			
Units: Subjects			
Female	1863	710	2573
Male	4	0	4

## End points

### End points reporting groups

Reporting group title	Cohort A: SC Herceptin by Needle/Syringe
Reporting group description: Subjects received SC Herceptin by an assisted administration as 600 milligrams (mg) every 3 weeks for a total of 18 doses/cycles. Each dose of SC Herceptin was taken from a single-use vial and injected by needle/syringe.	
Reporting group title	Cohort B: SC Herceptin by Single-Use Injection Device (SID)
Reporting group description: Subjects received SC Herceptin as 600 mg every 3 weeks for a total of 18 doses/cycles. Each dose of SC Herceptin was administered from a pre-filled SID. The first administration was performed by a healthcare professional (HCP). Subsequent doses were self-administered by subjects who were willing and judged competent by the HCP.	

### Primary: Percentage of Subjects With At Least 1 Adverse Event (AE) During the Treatment Period

End point title	Percentage of Subjects With At Least 1 Adverse Event (AE) During the Treatment Period <sup>[1]</sup>
End point description: Subjects were planned to receive a total of 18 cycles of SC Herceptin. An AE was defined as any untoward medical occurrence in a subjects administered SC Herceptin. Examples included unfavorable/unintended signs and symptoms, new or exacerbated disease, recurrence of intermittent condition, deterioration in laboratory value or other clinical test, or adverse procedure-related events. The percentage of subjects with at least 1 AE during the treatment period (regardless of severity or seriousness) was reported. Safety Population: All enrolled subjects who received at least one dose of study medication according to assigned treatment.	
End point type	Primary
End point timeframe: From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistics was planned to be reported in the endpoint.

End point values	Cohort A: SC Herceptin by Needle/Syringe	Cohort B: SC Herceptin by Single-Use Injection Device (SID)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1864	709		
Units: Percentage of Subjects				
number (not applicable)	88.6	89		

### Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Subjects With a Grade 3 or Higher AE During the Treatment Period



End point title	Percentage of Subjects With a Grade 3 or Higher AE During the Treatment Period <sup>[2]</sup>
-----------------	---

End point description:

Subjects were planned to receive a total of 18 cycles of SC Herceptin. An AE was defined as any untoward medical occurrence in a subject administered SC Herceptin. Examples included unfavorable/unintended signs and symptoms, new or exacerbated disease, recurrence of intermittent condition, deterioration in laboratory value or other clinical test, or adverse procedure-related events. AEs were graded according to National Cancer Institute Common Terminology Criteria Version 4.0. Grade 3 AEs were those considered severe or medically significant but not immediately life-threatening. Grade 4 AEs were those considered life-threatening and/or for which urgent intervention was indicated. Grade 5 AEs were those resulting in death. The percentage of subjects with a Grade 3 or higher (i.e., Grade 3 to 5) AE during the treatment period was reported. Safety Population.

End point type	Primary
----------------	---------

End point timeframe:

From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistics was planned to be reported in the endpoint.

End point values	Cohort A: SC Herceptin by Needle/Syringe	Cohort B: SC Herceptin by Single-Use Injection Device (SID)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1864	709		
Units: Percentage of Subjects				
number (confidence interval 95%)	24 (22.1 to 26)	21 (18.1 to 24.2)		

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Subjects With Treatment Interruption Due to an AE

End point title	Percentage of Subjects With Treatment Interruption Due to an AE <sup>[3]</sup>
-----------------	--

End point description:

Subjects were planned to receive a total of 18 cycles of SC Herceptin. An AE was defined as any untoward medical occurrence in a participant administered SC Herceptin. Examples included unfavorable/unintended signs and symptoms, new or exacerbated disease, recurrence of intermittent condition, deterioration in laboratory value or other clinical test, or adverse procedure-related events. The percentage of subjects with SC Herceptin treatment interrupted to assess or treat AEs was reported. Safety Population.

End point type	Primary
----------------	---------

End point timeframe:

From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year)

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistics was planned to be reported in the endpoint.

End point values	Cohort A: SC Herceptin by Needle/Syringe	Cohort B: SC Herceptin by Single-Use Injection Device (SID)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1864	709		
Units: Percentage of Subjects				
number (not applicable)	9.8	10.4		

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of Herceptin Cycles Received

End point title	Number of Herceptin Cycles Received <sup>[4]</sup>
-----------------	--

End point description:

Participants were planned to receive a total of 18 cycles of SC Herceptin. The median number of cycles actually received was reported. Safety Population. The endpoint also included an analysis of a subgroup of participants from Cohort B who received doses of self-administered SC Herceptin via SID.

End point type	Primary
----------------	---------

End point timeframe:

From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year)

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistics was planned to be reported in the endpoint.

End point values	Cohort A: SC Herceptin by Needle/Syringe	Cohort B: SC Herceptin by Single-Use Injection Device (SID)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1864	709		
Units: cycles				
median (full range (min-max))	18 (1 to 19)	18 (1 to 18)		

## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Subjects by Total Number of Herceptin Cycles Received

End point title	Percentage of Subjects by Total Number of Herceptin Cycles Received <sup>[5]</sup>
-----------------	--

End point description:

Participants were planned to receive a total of 18 cycles of SC Herceptin. The percentage of subjects was reported by the total number of cycles actually received. Because the data are presented non-cumulatively, this table reflects subjects distribution by the highest number of cycles received. Safety Population. The endpoint also included an analysis of a subgroup of subjects from Cohort B who received doses of self-administered SC Herceptin via SID.

End point type	Primary
----------------	---------

End point timeframe:

From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistics was planned to be reported in the endpoint.

End point values	Cohort A: SC Herceptin by Needle/Syringe	Cohort B: SC Herceptin by Single-Use Injection Device (SID)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1864	709		
Units: Percentage of Subjects				
number (not applicable)				
1 Cycle Received	1	0.8		
2 Cycles Received	0.5	0.4		
3 Cycles Received	0.5	0.1		
4 Cycles Received	1.2	0.7		
5 Cycles Received	0.8	0.6		
6 Cycles Received	0.5	0.1		
7 Cycles Received	0.7	0.8		
8 Cycles Received	0.9	0.3		
9 Cycles Received	0.2	0.6		
10 Cycles Received	0.3	0.1		
11 Cycles Received	0.4	0.3		
12 Cycles Received	0.9	0.8		
13 Cycles Received	0.2	0		
14 Cycles Received	0.5	0.6		
15 Cycles Received	0.5	0.4		
16 Cycles Received	0.6	0.3		
17 Cycles Received	1	1.1		
18 Cycles Received	89.2	91.8		
19 Cycles Received	0.2	0		

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Subjects Who Received Concomitant Cancer Therapy

End point title	Percentage of Subjects Who Received Concomitant Cancer Therapy <sup>[6]</sup>
-----------------	---

End point description:

Concomitant cancer treatment included chemotherapy, radiotherapy, and hormone therapy administered during the study. The percentage of subjects who received any of these concomitant therapies was reported. Safety Population.

End point type	Primary
----------------	---------

End point timeframe:

From Baseline to data cutoff of 10 March 2015 (up to approximately 3 years)

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistics was planned to be reported in the endpoint.

End point values	Cohort A: SC Herceptin by Needle/Syringe	Cohort B: SC Herceptin by Single-Use Injection Device (SID)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1864	709		
Units: Percentage of Subjects				
number (not applicable)				
Chemotherapy	63.9	58.2		
Radiotherapy	48.5	51.3		
Hormone Therapy	50.4	51.3		

## Statistical analyses

No statistical analyses for this end point

## Primary: Percentage of Subjects Who Received Concomitant Non-Cancer Therapy

End point title	Percentage of Subjects Who Received Concomitant Non-Cancer Therapy <sup>[7]</sup>
-----------------	---

End point description:

Concomitant non-cancer treatment included any pharmacologic interventions administered during the study other than chemotherapy, radiotherapy, or hormone therapy. The percentage of subjects who received any concomitant non-cancer therapies was reported. Safety Population.

End point type	Primary
----------------	---------

End point timeframe:

From Baseline to data cutoff of 10 March 2015 (up to approximately 3 years)

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistics was planned to be reported in the endpoint.

End point values	Cohort A: SC Herceptin by Needle/Syringe	Cohort B: SC Herceptin by Single-Use Injection Device (SID)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1864	709		
Units: Percentage of Subjects				
number (not applicable)	89.1	89.7		

## Statistical analyses

No statistical analyses for this end point

**Secondary: Percentage of Subjects Who Died by Data Cutoff of 10 March 2015**

End point title	Percentage of Subjects Who Died by Data Cutoff of 10 March 2015
-----------------	---

End point description:

The subjects of subjects who died from any cause was reported. ITT Population: All subjects enrolled into the study regardless of whether treatment was received.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline to time of event (maximum follow-up approximately 3 years as of data cutoff of 10 March 2015)

End point values	Cohort A: SC Herceptin by Needle/Syringe	Cohort B: SC Herceptin by Single-Use Injection Device (SID)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1864	709		
Units: Percentage of Subjects				
number (not applicable)	1.5	0.8		

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Percentage of Subjects Who Died from Baseline to Safety Follow-up Period**

End point title	Percentage of Subjects Who Died from Baseline to Safety Follow-up Period
-----------------	--

End point description:

The percentage of subjects who died from any cause was reported. ITT Population: All subjects enrolled into the study regardless of whether treatment was received. 4 Subjects were not included in the final analyses due to the lack of Principal Investigator signatures in the subjects specific casebooks.

End point type	Secondary
----------------	-----------

End point timeframe:

Safety Follow-up period, up to approximately 6 years

End point values	Cohort A: SC Herceptin by Needle/Syringe	Cohort B: SC Herceptin by Single-Use Injection Device (SID)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1865	708		
Units: Percentage of Subjects				
number (not applicable)	6.8	7.3		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects by Item Response to SID Satisfaction Questionnaire

End point title	Percentage of Subjects by Item Response to SID Satisfaction Questionnaire <sup>[8]</sup>
-----------------	--

End point description:

The SID satisfaction questionnaire was administered twice during study and asked subjects to respond to five statements using a Likert scale from "Strongly Disagree" to "Strongly Agree". Questionnaire items were: "I felt comfortable injecting the study drug by myself" (Comfortable), "The SID was convenient and easy to use" (Easy to Use), "I am confident giving myself an injection in the thigh with the SID" (Confident), "Taking all things into account I find self-administration using the SID satisfactory" (Satisfactory), "If given the opportunity I would choose to continue self-injecting the study drug using the SID in the future" (Continue). Subjects could select one response per questionnaire item. The percentage of subjects was reported by response given for each item on the SID satisfaction questionnaire. Safety Population. Only those who self-administered were included. The number of subjects who responded to the questionnaire item at each assessment (n) is shown.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 4 (cycle length 3 weeks) and last safety follow-up (LSFU) (approximately 1 year)

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Data for this endpoint was provided only for those arms which were planned to be reported.

End point values	Cohort B: SC Herceptin by Single-Use Injection Device (SID)			
Subject group type	Reporting group			
Number of subjects analysed	709			
Units: Percentage of Subjects				
number (not applicable)				
Cycle 4: Comfortable, Strongly Disagree (n=514)	4.7			
Cycle 4: Comfortable, Disagree (n=514)	2.3			
Cycle 4: Comfortable, Unsure (n=514)	4.6			
Cycle 4: Comfortable, Agree (n=514)	41.6			
Cycle 4: Comfortable, Strongly Agree (n=514)	43.6			
Cycle 4: Comfortable, Response Missing (n=514)	0.2			
Cycle 4: Easy to Use, Strongly Disagree (n=514)	3.7			
Cycle 4: Easy to Use, Disagree (n=514)	0.6			
Cycle 4: Easy to Use, Unsure (n=514)	1.8			
Cycle 4: Easy to Use, Agree (n=514)	37.7			

Cycle 4: Easy to Use, Strongly Agree (n=514)	56			
Cycle 4: Easy to Use, Response Missing (n=514)	0.2			
Cycle 4: Confident, Strongly Disagree (n=514)	3.9			
Cycle 4: Confident, Disagree (n=514)	0.8			
Cycle 4: Confident, Unsure (n=514)	7.2			
Cycle 4: Confident, Agree (n=514)	42.8			
Cycle 4: Confident, Strongly Agree (n=514)	45.1			
Cycle 4: Confident, Response Missing (n=514)	0.2			
Cycle 4: Satisfactory, Strongly Disagree (n=514)	3.9			
Cycle 4: Satisfactory, Disagree (n=514)	0.6			
Cycle 4: Satisfactory, Unsure (n=514)	2.7			
Cycle 4: Satisfactory, Agree (n=514)	38.7			
Cycle 4: Satisfactory, Strongly Agree (n=514)	53.9			
Cycle 4: Satisfactory, Response Missing (n=514)	0.2			
Cycle 4: Continue, Strongly Disagree (n=514)	3.9			
Cycle 4: Continue, Disagree (n=514)	1.4			
Cycle 4: Continue, Unsure (n=514)	5.3			
Cycle 4: Continue, Agree (n=514)	33.5			
Cycle 4: Continue, Strongly Agree (n=514)	55.8			
Cycle 4: Continue, Response Missing (n=514)	0.2			
LSFU: Comfortable, Strongly Disagree (n=415)	3.6			
LSFU: Comfortable, Disagree (n=415)	3.1			
LSFU: Comfortable, Unsure (n=415)	5.3			
LSFU: Comfortable, Agree (n=415)	35.9			
LSFU: Comfortable, Strongly Agree (n=415)	51.8			
LSFU: Comfortable, Response Missing (n=415)	0.2			
LSFU: Easy to Use, Strongly Disagree (n=415)	3.9			
LSFU: Easy to Use, Disagree (n=415)	1			
LSFU: Easy to Use, Unsure (n=415)	1.7			
LSFU: Easy to Use, Agree (n=415)	34.9			
LSFU: Easy to Use, Strongly Agree (n=415)	58.6			
LSFU: Easy to Use, Response Missing (n=415)	0			
LSFU: Confident, Strongly Disagree (n=415)	4.6			
LSFU: Confident, Disagree (n=415)	1.2			
LSFU: Confident, Unsure (n=415)	4.3			
LSFU: Confident, Agree (n=415)	33.3			
LSFU: Confident, Strongly Agree (n=415)	56.6			
LSFU: Confident, Response Missing (n=415)	0			

LSFU: Satisfactory, Strongly Disagree (n=415)	4.3			
LSFU: Satisfactory, Disagree (n=415)	1.2			
LSFU: Satisfactory, Unsure (n=415)	2.2			
LSFU: Satisfactory, Agree (n=415)	30.8			
LSFU: Satisfactory, Strongly Agree (n=415)	61.2			
LSFU: Satisfactory, Response Missing (n=415)	0.2			
LSFU: Continue, Strongly Disagree (n=415)	4.6			
LSFU: Continue, Disagree (n=415)	1.2			
LSFU: Continue, Unsure (n=415)	2.9			
LSFU: Continue, Agree (n=415)	28.2			
LSFU: Continue, Strongly Agree (n=415)	63.1			
LSFU: Continue, Response Missing (n=415)	0			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Disease Free Survival Rate

End point title	Disease Free Survival Rate
End point description:	
ITT population in SFU, 4 Participants were not included in the final analyses due to the lack of Principal Investigator signatures in the participant specific casebooks.	
End point type	Secondary
End point timeframe:	
From Baseline to Time of Event (Up to Approximately 6 Years)	

End point values	Cohort A: SC Herceptin by Needle/Syringe	Cohort B: SC Herceptin by Single-Use Injection Device (SID)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1865	708		
Units: Ratio				
number (confidence interval 95%)				
0.5 Year	0.990 (0.984 to 0.993)	0.987 (0.976 to 0.993)		
1 Year	0.975 (0.967 to 0.981)	0.976 (0.961 to 0.98)		
1.5 Year	0.960 (0.950 to 0.968)	0.957 (0.939 to 0.970)		
2 Years	0.934 (0.921 to 0.944)	0.939 (0.918 to 0.955)		
3 Years	0.904 (0.889 to 0.917)	0.896 (0.870 to 0.916)		



4 Years	0.881 (0.865 to 0.896)	0.874 (0.847 to 0.897)		
5 Years	0.868 (0.851 to 0.883)	0.863 (0.835 to 0.887)		
6 Years	0.851 (0.833 to 0.867)	0.853 (0.824 to 0.878)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall Survival Rate

End point title	Overall Survival Rate
-----------------	-----------------------

End point description:

ITT Population. 4 Participants were not included in the final analyses due to the lack of Principal Investigator signatures in the participant specific casebooks.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline to Time of Event (Up to Approximately 6 Years)

End point values	Cohort A: SC Herceptin by Needle/Syringe	Cohort B: SC Herceptin by Single-Use Injection Device (SID)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1865	708		
Units: Ratio				
number (confidence interval 95%)				
0.5 Year	0.999 (0.996 to 1.000)	0.996 (0.987 to 0.999)		
1 year	0.998 (0.994 to 0.999)	0.994 (0.985 to 0.998)		
1.5 year	0.993 (0.988 to 0.996)	0.990 (0.979 to 0.995)		
2 Years	0.985 (0.979 to 0.990)	0.985 (0.973 to 0.992)		
3 Years	0.968 (0.958 to 0.975)	0.960 (0.942 to 0.972)		
4 Years	0.947 (0.935 to 0.956)	0.950 (0.931 to 0.965)		
5 Years	0.937 (0.925 to 0.948)	0.929 (0.907 to 0.947)		
6 Years	0.927 (0.913 to 0.938)	0.921 (0.897 to 0.939)		

## Statistical analyses



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From Day 1 up to 19 cycles (approximately 1 year) for the Treatment Period.

From Data Cutoff up to approximately 6 years for the Safety Follow-up Period (SFU).

Adverse event reporting additional description:

3 AEs during treatment resulted in eventual death, under the respective AE terms in Cohort A. 1 death during treatment, captured in "Number of deaths (all causes)" in Cohort A. Remaining 2 deaths included in SFU. SFU Period: no non-SAEs occurred at 5% threshold, 4 subjects excluded due to missing Principal Investigator signature in casebooks.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.1
--------------------	------

### Reporting groups

Reporting group title	Cohort A: SC Herceptin by Needle/Syringe
-----------------------	--

Reporting group description:

Subjects received SC Herceptin by an assisted administration as 600 mg every 3 weeks for a total of 18 doses/cycles. Each dose of SC Herceptin was taken from a single-use vial and injected by needle/syringe.

Reporting group title	Cohort A: SC Herceptin by Needle/Syringe Safety Follow-up
-----------------------	---

Reporting group description:

Subjects received SC Herceptin by an assisted administration as 600 mg every 3 weeks for a total of 18 doses/cycles. Each dose of SC Herceptin was taken from a single-use vial and injected by needle/syringe.

Reporting group title	Cohort B: SC Herceptin by SID Safety Follow-up
-----------------------	--

Reporting group description:

Subjects received SC Herceptin as 600 mg every 3 weeks for a total of 18 doses/cycles. Each dose of SC Herceptin was administered from a pre-filled SID. The first administration was performed by an HCP. Subsequent doses were self-administered by subjects who were willing and judged competent by the HCP.

Reporting group title	Cohort B: SC Herceptin by Single-Use Injection Device (SID)
-----------------------	---

Reporting group description:

Subjects received SC Herceptin as 600 mg every 3 weeks for a total of 18 doses/cycles. Each dose of SC Herceptin was administered from a pre-filled SID. The first administration was performed by an HCP. Subsequent doses were self-administered by subjects who were willing and judged competent by the HCP.

Serious adverse events	Cohort A: SC Herceptin by Needle/Syringe	Cohort A: SC Herceptin by Needle/Syringe Safety Follow-up	Cohort B: SC Herceptin by SID Safety Follow-up
Total subjects affected by serious adverse events			
subjects affected / exposed	242 / 1864 (12.98%)	202 / 1862 (10.85%)	53 / 707 (7.50%)
number of deaths (all causes)	28	98	45
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Uterine leiomyoma			

subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Benign pancreatic neoplasm			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Borderline serous tumour of ovary			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer			
subjects affected / exposed	1 / 1864 (0.05%)	15 / 1862 (0.81%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 1	0 / 15	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clear cell renal cell carcinoma			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon cancer			
subjects affected / exposed	0 / 1864 (0.00%)	2 / 1862 (0.11%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometrial cancer			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intraductal proliferative breast lesion			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung adenocarcinoma			

subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian fibroma			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal adenocarcinoma			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Schwannoma			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroid adenoma			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine Cancer			
subjects affected / exposed	0 / 1864 (0.00%)	2 / 1862 (0.11%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Papillary Thyroid Cancer			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian Cancer Recurrent			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian Cancer			

subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic Gastric Cancer			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung Neoplasm Malignant			
subjects affected / exposed	0 / 1864 (0.00%)	2 / 1862 (0.11%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Lung Cancer Metastatic			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal Carcinoma			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric Cancer			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenocarcinoma of Colon			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Vulval Cancer			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroid Cancer			

subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal Cell Carcinoma			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic Carcinoma			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Ovarian Epithelial Cancer Metastatic			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Non-Hodgkin's Lymphoma			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphocytic Lymphoma			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive Lobular Breast Carcinoma			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive Ductal Breast Carcinoma			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular Carcinoma			

subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glioma			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glioblastoma			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometrial Adenocarcinoma			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon Cancer Metastatic			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Chondroma			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast Sarcoma			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast Neoplasm			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder Cancer			



subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal Cell Carcinoma			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Synovial Sarcoma Metastatic			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Malignant Melanoma			
subjects affected / exposed	0 / 1864 (0.00%)	3 / 1862 (0.16%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypertension			
subjects affected / exposed	2 / 1864 (0.11%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive crisis			
subjects affected / exposed	1 / 1864 (0.05%)	2 / 1862 (0.11%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic aneurysm			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arterial stenosis			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			

subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic hypotension			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Phlebitis			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis limb			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thromboangiitis Obliterans			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicose Vein			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive Urgency			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Anembryonic Gestation			

subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	11 / 1864 (0.59%)	1 / 1862 (0.05%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 12	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device breakage			
subjects affected / exposed	1 / 1864 (0.05%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthenia			
subjects affected / exposed	1 / 1864 (0.05%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest discomfort			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	1 / 1864 (0.05%)	2 / 1862 (0.11%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 1864 (0.00%)	6 / 1862 (0.32%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 6	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 6	0 / 1
Device defective			

subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza like illness			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal inflammation			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-cardiac chest pain			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden Death			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Immune system disorders			
Drug hypersensitivity			
subjects affected / exposed	2 / 1864 (0.11%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypersensitivity			

subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaphylactic Shock			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Uterine polyp			
subjects affected / exposed	2 / 1864 (0.11%)	3 / 1862 (0.16%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast fibrosis			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometrial hypertrophy			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian cyst			
subjects affected / exposed	1 / 1864 (0.05%)	2 / 1862 (0.11%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postmenopausal haemorrhage			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine haemorrhage			
subjects affected / exposed	1 / 1864 (0.05%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast Necrosis			

subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast Calcifications			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometrial Hyperplasia			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical Dysplasia			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fibrocystic Breast Disease			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vaginal Haemorrhage			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	2 / 1864 (0.11%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	2 / 1864 (0.11%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			

subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 1864 (0.00%)	4 / 1862 (0.21%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Dyspnoea exertional			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organising pneumonia			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Painful respiration			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleurisy			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic Obstructive Pulmonary Disease			

subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive Airways Disorder			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural Effusion			
subjects affected / exposed	0 / 1864 (0.00%)	2 / 1862 (0.11%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Epistaxis			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary Sarcoidosis			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	2 / 1864 (0.11%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	1 / 1864 (0.05%)	2 / 1862 (0.11%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Panic attack			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychotic disorder			



subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Investigations</b>			
Ejection fraction decreased			
subjects affected / exposed	3 / 1864 (0.16%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	2 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
White blood cell count decreased			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood urea increased			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrocardiogram QT prolonged			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutrophil count decreased			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Injury, poisoning and procedural complications</b>			
Radiation pneumonitis			
subjects affected / exposed	2 / 1864 (0.11%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	1 / 1864 (0.05%)	1 / 1862 (0.05%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Wound dehiscence			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Concussion			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fibula fracture			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture displacement			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laceration			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar vertebral fracture			
subjects affected / exposed	1 / 1864 (0.05%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Patella fracture			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic fracture			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radius fracture			

subjects affected / exposed	1 / 1864 (0.05%)	2 / 1862 (0.11%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seroma			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic arthropathy			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulna fracture			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pubis Fracture			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower Limb Fracture			

subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foreign Body Aspiration			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot Fracture			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	2 / 707 (0.28%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wrist Fracture			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thoracic Vertebral Fracture			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post Procedural Haematoma			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint Dislocation			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incisional Hernia			

subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head Injury			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Craniocerebral Injury			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intentional Overdose			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal Compression Fracture			
subjects affected / exposed	0 / 1864 (0.00%)	2 / 1862 (0.11%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib Fracture			
subjects affected / exposed	0 / 1864 (0.00%)	2 / 1862 (0.11%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus Fracture			
subjects affected / exposed	0 / 1864 (0.00%)	2 / 1862 (0.11%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clavicle Fracture			

subjects affected / exposed	0 / 1864 (0.00%)	2 / 1862 (0.11%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral Neck Fracture			
subjects affected / exposed	0 / 1864 (0.00%)	3 / 1862 (0.16%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ankle Fracture			
subjects affected / exposed	0 / 1864 (0.00%)	3 / 1862 (0.16%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac failure congestive			
subjects affected / exposed	10 / 1864 (0.54%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	9 / 10	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	2 / 1864 (0.11%)	6 / 1862 (0.32%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	2 / 3	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	2 / 1864 (0.11%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	2 / 1864 (0.11%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular dysfunction			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial ischaemia			

subjects affected / exposed	2 / 1864 (0.11%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			
subjects affected / exposed	2 / 1864 (0.11%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	1 / 1864 (0.05%)	3 / 1862 (0.16%)	3 / 707 (0.42%)
occurrences causally related to treatment / all	0 / 1	0 / 3	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Atrial thrombosis			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block second degree			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocarditis			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palpitations			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stress cardiomyopathy			

subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular arrhythmia			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracardiac Thrombus			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial Infarction			
subjects affected / exposed	0 / 1864 (0.00%)	6 / 1862 (0.32%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute Coronary Syndrome			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina Pectoris			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriosclerosis Coronary Artery			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Atrial Flutter			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial Tachycardia			



subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac Hypertrophy			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cardio-Respiratory Arrest			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Tachycardia			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Headache			
subjects affected / exposed	2 / 1864 (0.11%)	2 / 1862 (0.11%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	1 / 1864 (0.05%)	2 / 1862 (0.11%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aphasia			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid sinus syndrome			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral ischaemia			

subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	1 / 1864 (0.05%)	2 / 1862 (0.11%)	2 / 707 (0.28%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Depressed level of consciousness			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised tonic-clonic seizure			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral sensorimotor neuropathy			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tension headache			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			

subjects affected / exposed	1 / 1864 (0.05%)	1 / 1862 (0.05%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Relapsing-Remitting Multiple Sclerosis			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dementia Alzheimer's Type			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dementia			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral Infarction			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Amyotrophic Lateral Sclerosis			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cerebral Haemorrhage			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cerebrovascular Disorder			

subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Dizziness			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic Stroke			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydrocephalus			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Sciatica			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Febrile neutropenia			
subjects affected / exposed	39 / 1864 (2.09%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	5 / 39	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	9 / 1864 (0.48%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 11	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile bone marrow aplasia			
subjects affected / exposed	2 / 1864 (0.11%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			

subjects affected / exposed	3 / 1864 (0.16%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	2 / 1864 (0.11%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukopenia			
subjects affected / exposed	2 / 1864 (0.11%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thymus enlargement			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenopathy			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	2 / 1864 (0.11%)	1 / 1862 (0.05%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meniere's disease			

subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Keratitis			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	8 / 1864 (0.43%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 9	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	5 / 1864 (0.27%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 6	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	3 / 1864 (0.16%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	2 / 1864 (0.11%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	2 / 1864 (0.11%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			

subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal discomfort			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	1 / 1864 (0.05%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis erosive			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal pain			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal polyp			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenic colitis			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subileus			

subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal Hernia			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal Fissure			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small Intestinal Obstruction			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum Intestinal			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Food Poisoning			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiatus Hernia			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal Obstruction			



subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper Gastrointestinal Haemorrhage			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	2 / 1864 (0.11%)	3 / 1862 (0.16%)	2 / 707 (0.28%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis chronic			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic Failure			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic Steatosis			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bile Duct Obstruction			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bile Duct Stenosis			

subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cholangitis Acute			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermatitis bullous			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema nodosum			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			
subjects affected / exposed	1 / 1864 (0.05%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxic skin eruption			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient acantholytic dermatosis			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lichen Sclerosus			

subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema			
subjects affected / exposed	0 / 1864 (0.00%)	2 / 1862 (0.11%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Renal failure			
subjects affected / exposed	2 / 1864 (0.11%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary incontinence			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary Bladder Polyp			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrotic Syndrome			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Nephrolithiasis			

subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal Colic			
subjects affected / exposed	0 / 1864 (0.00%)	2 / 1862 (0.11%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute Kidney Injury			
subjects affected / exposed	0 / 1864 (0.00%)	2 / 1862 (0.11%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroiditis Subacute			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Osteoarthritis			
subjects affected / exposed	2 / 1864 (0.11%)	1 / 1862 (0.05%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis			
subjects affected / exposed	1 / 1864 (0.05%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Intervertebral disc protrusion			
subjects affected / exposed	1 / 1864 (0.05%)	1 / 1862 (0.05%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar spinal stenosis			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myalgia			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rheumatoid arthritis			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal Stenosis			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scleroderma			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal Disorder			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mobility Decreased			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Exostosis			

subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Neutropenic sepsis			
subjects affected / exposed	9 / 1864 (0.48%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	1 / 9	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	6 / 1864 (0.32%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	1 / 6	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	5 / 1864 (0.27%)	8 / 1862 (0.43%)	2 / 707 (0.28%)
occurrences causally related to treatment / all	0 / 5	0 / 8	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 0
Urinary tract infection			
subjects affected / exposed	3 / 1864 (0.16%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mastitis			
subjects affected / exposed	3 / 1864 (0.16%)	4 / 1862 (0.21%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	4 / 1864 (0.21%)	4 / 1862 (0.21%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			

subjects affected / exposed	3 / 1864 (0.16%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	4 / 1864 (0.21%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	2 / 1864 (0.11%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	2 / 1864 (0.11%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast abscess			
subjects affected / exposed	2 / 1864 (0.11%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	2 / 1864 (0.11%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infectious colitis			
subjects affected / exposed	2 / 1864 (0.11%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	2 / 1864 (0.11%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			

subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess of external auditory meatus			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendiceal abscess			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bartholin's abscess			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cellulitis			
subjects affected / exposed	0 / 1864 (0.00%)	2 / 1862 (0.11%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopneumonia			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			



subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dengue fever			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	1 / 1864 (0.05%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile infection			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis rotavirus			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis B			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	1 / 1864 (0.05%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal sepsis			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lobar pneumonia			

subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Localised infection			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infection			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymph node tuberculosis			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningoencephalitis bacterial			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periorbital cellulitis			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	1 / 1864 (0.05%)	2 / 1862 (0.11%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			

subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin infection			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Soft tissue infection			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheobronchitis			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vaginal infection			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			

subjects affected / exposed	0 / 1864 (0.00%)	2 / 1862 (0.11%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia Influenzal			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia Streptococcal			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary Sepsis			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Post Procedural Cellulitis			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kidney Infection			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis Viral			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterobacter Sepsis			

subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic Gangrene			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dengue Haemorrhagic Fever			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic Sinusitis			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Biliary Tract Infection			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 1864 (0.00%)	2 / 1862 (0.11%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia Sepsis			
subjects affected / exposed	0 / 1864 (0.00%)	2 / 1862 (0.11%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyperglycaemia			

subjects affected / exposed	2 / 1864 (0.11%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrolyte imbalance			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gout			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	1 / 1864 (0.05%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Decreased Appetite			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes Mellitus			
subjects affected / exposed	0 / 1864 (0.00%)	1 / 1862 (0.05%)	0 / 707 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 1864 (0.00%)	0 / 1862 (0.00%)	1 / 707 (0.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Cohort B: SC Herceptin by Single- Use Injection Device		
-------------------------------	--	--	--

	(SID)		
Total subjects affected by serious adverse events			
subjects affected / exposed	84 / 709 (11.85%)		
number of deaths (all causes)	6		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Uterine leiomyoma			
subjects affected / exposed	2 / 709 (0.28%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Benign pancreatic neoplasm			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Borderline serous tumour of ovary			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Breast cancer			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Clear cell renal cell carcinoma			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colon cancer			
subjects affected / exposed	1 / 709 (0.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Endometrial cancer			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Intraductal proliferative breast lesion				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lung adenocarcinoma				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Ovarian fibroma				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rectal adenocarcinoma				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Schwannoma				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Thyroid adenoma				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Uterine Cancer				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Papillary Thyroid Cancer				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ovarian Cancer Recurrent				



subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ovarian Cancer				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metastatic Gastric Cancer				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lung Neoplasm Malignant				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lung Cancer Metastatic				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal Carcinoma				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastric Cancer				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Adenocarcinoma of Colon				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Vulval Cancer				

subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thyroid Cancer			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal Cell Carcinoma			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatic Carcinoma			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ovarian Epithelial Cancer Metastatic			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Non-Hodgkin's Lymphoma			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lymphocytic Lymphoma			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Invasive Lobular Breast Carcinoma			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Invasive Ductal Breast Carcinoma			

subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatocellular Carcinoma			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Glioma			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Glioblastoma			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endometrial Adenocarcinoma			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colon Cancer Metastatic			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chondroma			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Breast Sarcoma			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Breast Neoplasm			

subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bladder Cancer			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Basal Cell Carcinoma			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Synovial Sarcoma Metastatic			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Malignant Melanoma			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypertensive crisis			
subjects affected / exposed	1 / 709 (0.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Aortic aneurysm			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arterial stenosis			

subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Deep vein thrombosis				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Orthostatic hypotension				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Phlebitis				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Venous thrombosis				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Venous thrombosis limb				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Thromboangiitis Obliterans				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Varicose Vein				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypertensive Urgency				

subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pregnancy, puerperium and perinatal conditions			
Anembryonic Gestation			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	7 / 709 (0.99%)		
occurrences causally related to treatment / all	0 / 8		
deaths causally related to treatment / all	0 / 0		
Device breakage			
subjects affected / exposed	1 / 709 (0.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General physical health deterioration			
subjects affected / exposed	1 / 709 (0.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Asthenia			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chest discomfort			
subjects affected / exposed	1 / 709 (0.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Chest pain			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Death				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Device defective				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Fatigue				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Influenza like illness				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mucosal inflammation				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Non-cardiac chest pain				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oedema peripheral				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sudden Death				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Immune system disorders				

Drug hypersensitivity				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypersensitivity				
subjects affected / exposed	2 / 709 (0.28%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Anaphylactic Shock				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Reproductive system and breast disorders				
Uterine polyp				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Breast fibrosis				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Endometrial hypertrophy				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ovarian cyst				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Postmenopausal haemorrhage				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			



Uterine haemorrhage			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Breast Necrosis			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Breast Calcifications			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endometrial Hyperplasia			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cervical Dysplasia			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fibrocystic Breast Disease			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vaginal Haemorrhage			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Dyspnoea				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonitis				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pulmonary embolism				
subjects affected / exposed	2 / 709 (0.28%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Dyspnoea exertional				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Organising pneumonia				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Painful respiration				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pleurisy				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pulmonary oedema				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory failure				

subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chronic Obstructive Pulmonary Disease			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Obstructive Airways Disorder			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pleural Effusion			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Epistaxis			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary Sarcoidosis			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Depression			
subjects affected / exposed	1 / 709 (0.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Panic attack			

subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychotic disorder			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
Ejection fraction decreased			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
White blood cell count decreased			
subjects affected / exposed	1 / 709 (0.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood urea increased			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Electrocardiogram QT prolonged			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neutrophil count decreased			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Radiation pneumonitis			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Hip fracture				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Wound dehiscence				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 4			
deaths causally related to treatment / all	0 / 0			
Concussion				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Fibula fracture				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Fracture displacement				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Laceration				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Lumbar vertebral fracture				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Patella fracture				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pelvic fracture				

subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Radius fracture				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Seroma				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Spinal fracture				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tibia fracture				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Traumatic arthropathy				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Ulna fracture				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Wound				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pubis Fracture				

subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lower Limb Fracture				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Foreign Body Aspiration				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Foot Fracture				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Fall				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Wrist Fracture				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Thoracic Vertebral Fracture				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Post Procedural Haematoma				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Joint Dislocation				

subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Incisional Hernia			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Head Injury			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fracture			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Craniocerebral Injury			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intentional Overdose			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal Compression Fracture			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rib Fracture			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Humerus Fracture			



subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Clavicle Fracture			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Femoral Neck Fracture			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ankle Fracture			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Cardiac failure congestive			
subjects affected / exposed	1 / 709 (0.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Atrial fibrillation			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Angina unstable			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Coronary artery disease			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Left ventricular dysfunction			

subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Myocardial ischaemia				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pericarditis				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Supraventricular tachycardia				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Acute myocardial infarction				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atrial thrombosis				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atrioventricular block second degree				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Myocarditis				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Palpitations				

subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Stress cardiomyopathy			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ventricular arrhythmia			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intracardiac Thrombus			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myocardial Infarction			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute Coronary Syndrome			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Angina Pectoris			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arteriosclerosis Coronary Artery			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atrial Flutter			

subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atrial Tachycardia			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac Hypertrophy			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardio-Respiratory Arrest			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tachycardia			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Syncope			
subjects affected / exposed	1 / 709 (0.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Aphasia			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Carotid sinus syndrome			

subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cerebral ischaemia				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cerebrovascular accident				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Depressed level of consciousness				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Epilepsy				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Generalised tonic-clonic seizure				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Peripheral sensorimotor neuropathy				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Presyncope				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tension headache				

subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Transient ischaemic attack				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Seizure				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Relapsing-Remitting Multiple Sclerosis				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dementia Alzheimer's Type				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dementia				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cerebral Infarction				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Amyotrophic Lateral Sclerosis				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cerebral Haemorrhage				

subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebrovascular Disorder			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dizziness			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemorrhagic Stroke			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hydrocephalus			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sciatica			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Febrile neutropenia			
subjects affected / exposed	14 / 709 (1.97%)		
occurrences causally related to treatment / all	1 / 17		
deaths causally related to treatment / all	0 / 0		
Neutropenia			
subjects affected / exposed	6 / 709 (0.85%)		
occurrences causally related to treatment / all	1 / 6		
deaths causally related to treatment / all	0 / 0		
Febrile bone marrow aplasia			

subjects affected / exposed	2 / 709 (0.28%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Anaemia			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Leukocytosis			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Leukopenia			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancytopenia			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thymus enlargement			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lymphadenopathy			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombocytopenia			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ear and labyrinth disorders			
Vertigo			



subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Meniere's disease			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Keratitis			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	4 / 709 (0.56%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
Nausea			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatitis			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal pain upper			
subjects affected / exposed	1 / 709 (0.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pancreatitis acute			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vomiting			

subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal pain			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal discomfort			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colitis			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Constipation			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastritis erosive			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal pain			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intestinal polyp			
subjects affected / exposed	1 / 709 (0.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Neutropenic colitis			

subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Subileus				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Inguinal Hernia				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Anal Fissure				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastritis				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Small Intestinal Obstruction				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diverticulum Intestinal				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Food Poisoning				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hiatus Hernia				

subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intestinal Obstruction			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Upper Gastrointestinal Haemorrhage			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	1 / 709 (0.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cholecystitis chronic			
subjects affected / exposed	1 / 709 (0.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cholecystitis			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatic Failure			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatic Steatosis			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bile Duct Obstruction			

subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bile Duct Stenosis			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholangitis Acute			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	1 / 709 (0.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dermatitis bullous			
subjects affected / exposed	1 / 709 (0.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Erythema nodosum			
subjects affected / exposed	1 / 709 (0.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rash			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Toxic skin eruption			
subjects affected / exposed	1 / 709 (0.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Transient acantholytic dermatosis			

subjects affected / exposed	1 / 709 (0.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lichen Sclerosus			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Erythema			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Renal failure			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hydronephrosis			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary incontinence			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary retention			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary Bladder Polyp			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nephrotic Syndrome			

subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nephrolithiasis			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematuria			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal Colic			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute Kidney Injury			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	1 / 709 (0.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Thyroiditis Subacute			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Osteoarthritis			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Arthritis				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intervertebral disc protrusion				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lumbar spinal stenosis				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Myalgia				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rheumatoid arthritis				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Spinal Stenosis				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Scleroderma				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Musculoskeletal Disorder				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mobility Decreased				



subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Exostosis			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arthralgia			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Neutropenic sepsis			
subjects affected / exposed	1 / 709 (0.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Device related infection			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	1 / 709 (0.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection			
subjects affected / exposed	2 / 709 (0.28%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Mastitis			
subjects affected / exposed	2 / 709 (0.28%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Cellulitis			

subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Lower respiratory tract infection				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Appendicitis				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Upper respiratory tract infection				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Breast abscess				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Erysipelas				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infectious colitis				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pyelonephritis acute				

subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Viral infection				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Infective exacerbation of chronic obstructive airways disease				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Abscess of external auditory meatus				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Appendiceal abscess				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bartholin's abscess				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Breast cellulitis				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Bronchitis				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Bronchopneumonia				

subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Clostridium difficile infection				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dengue fever				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diverticulitis				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Febrile infection				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis rotavirus				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Hepatitis B				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Herpes zoster				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intestinal sepsis				

subjects affected / exposed	1 / 709 (0.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Lobar pneumonia			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Localised infection			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung infection			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lymph node tuberculosis			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Meningoencephalitis bacterial			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Periorbital cellulitis			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia bacterial			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Postoperative wound infection			

subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pyelonephritis				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory tract infection				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Skin infection				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Soft tissue infection				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Staphylococcal infection				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Tracheobronchitis				
subjects affected / exposed	0 / 709 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Urosepsis				
subjects affected / exposed	1 / 709 (0.14%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Vaginal infection				

subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Wound infection			
subjects affected / exposed	1 / 709 (0.14%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia Influenzal			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia Streptococcal			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary Sepsis			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post Procedural Cellulitis			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Kidney Infection			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis Viral			

subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Enterobacter Sepsis			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endocarditis			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diabetic Gangrene			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dengue Haemorrhagic Fever			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chronic Sinusitis			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Biliary Tract Infection			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infection			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Escherichia Sepsis			



subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Electrolyte imbalance			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gout			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypokalaemia			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyponatraemia			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Decreased Appetite			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diabetes Mellitus			
subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperkalaemia			

subjects affected / exposed	0 / 709 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Cohort A: SC Herceptin by Needle/Syringe	Cohort A: SC Herceptin by Needle/Syringe Safety Follow-up	Cohort B: SC Herceptin by SID Safety Follow-up
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1499 / 1864 (80.42%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
Investigations			
Ejection fraction decreased			
subjects affected / exposed	80 / 1864 (4.29%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	85	0	0
Injury, poisoning and procedural complications			
Radiation skin injury			
subjects affected / exposed	161 / 1864 (8.64%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	172	0	0
Vascular disorders			
Hot flush			
subjects affected / exposed	164 / 1864 (8.80%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	179	0	0
Hypertension			
subjects affected / exposed	142 / 1864 (7.62%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	183	0	0
Nervous system disorders			
Headache			
subjects affected / exposed	228 / 1864 (12.23%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	344	0	0
Neuropathy peripheral			
subjects affected / exposed	140 / 1864 (7.51%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	164	0	0
Paraesthesia			
subjects affected / exposed	112 / 1864 (6.01%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	130	0	0

Dizziness			
subjects affected / exposed	111 / 1864 (5.95%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	143	0	0
Peripheral sensory neuropathy			
subjects affected / exposed	94 / 1864 (5.04%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	102	0	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	381 / 1864 (20.44%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	496	0	0
Asthenia			
subjects affected / exposed	221 / 1864 (11.86%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	327	0	0
Pyrexia			
subjects affected / exposed	185 / 1864 (9.92%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	231	0	0
Oedema peripheral			
subjects affected / exposed	160 / 1864 (8.58%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	185	0	0
Injection site erythema			
subjects affected / exposed	128 / 1864 (6.87%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	326	0	0
Mucosal inflammation			
subjects affected / exposed	105 / 1864 (5.63%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	126	0	0
Injection site pain			
subjects affected / exposed	117 / 1864 (6.28%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	190	0	0
Injection site reaction			
subjects affected / exposed	101 / 1864 (5.42%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	279	0	0
Pain			
subjects affected / exposed	63 / 1864 (3.38%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	70	0	0
Blood and lymphatic system disorders			

Anaemia			
subjects affected / exposed	130 / 1864 (6.97%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	159	0	0
Neutropenia			
subjects affected / exposed	101 / 1864 (5.42%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	156	0	0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	380 / 1864 (20.39%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	540	0	0
Nausea			
subjects affected / exposed	274 / 1864 (14.70%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	362	0	0
Constipation			
subjects affected / exposed	153 / 1864 (8.21%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	200	0	0
Vomiting			
subjects affected / exposed	129 / 1864 (6.92%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	160	0	0
Stomatitis			
subjects affected / exposed	116 / 1864 (6.22%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	140	0	0
Abdominal pain			
subjects affected / exposed	87 / 1864 (4.67%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	104	0	0
Dyspepsia			
subjects affected / exposed	69 / 1864 (3.70%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	80	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	190 / 1864 (10.19%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	223	0	0
Dyspnoea			
subjects affected / exposed	115 / 1864 (6.17%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	126	0	0

Epistaxis subjects affected / exposed occurrences (all)	109 / 1864 (5.85%) 135	0 / 1862 (0.00%) 0	0 / 707 (0.00%) 0
Skin and subcutaneous tissue disorders			
Rash subjects affected / exposed occurrences (all)	177 / 1864 (9.50%) 251	0 / 1862 (0.00%) 0	0 / 707 (0.00%) 0
Erythema subjects affected / exposed occurrences (all)	156 / 1864 (8.37%) 223	0 / 1862 (0.00%) 0	0 / 707 (0.00%) 0
Alopecia subjects affected / exposed occurrences (all)	163 / 1864 (8.74%) 170	0 / 1862 (0.00%) 0	0 / 707 (0.00%) 0
Pruritus subjects affected / exposed occurrences (all)	115 / 1864 (6.17%) 136	0 / 1862 (0.00%) 0	0 / 707 (0.00%) 0
Psychiatric disorders			
Insomnia subjects affected / exposed occurrences (all)	108 / 1864 (5.79%) 125	0 / 1862 (0.00%) 0	0 / 707 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	362 / 1864 (19.42%) 471	0 / 1862 (0.00%) 0	0 / 707 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	260 / 1864 (13.95%) 349	0 / 1862 (0.00%) 0	0 / 707 (0.00%) 0
Pain in extremity subjects affected / exposed occurrences (all)	194 / 1864 (10.41%) 248	0 / 1862 (0.00%) 0	0 / 707 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	114 / 1864 (6.12%) 136	0 / 1862 (0.00%) 0	0 / 707 (0.00%) 0
Musculoskeletal pain			

subjects affected / exposed	89 / 1864 (4.77%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	107	0	0
Bone pain			
subjects affected / exposed	70 / 1864 (3.76%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	80	0	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	146 / 1864 (7.83%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	190	0	0
Upper respiratory tract infection			
subjects affected / exposed	113 / 1864 (6.06%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	132	0	0
Urinary tract infection			
subjects affected / exposed	94 / 1864 (5.04%)	0 / 1862 (0.00%)	0 / 707 (0.00%)
occurrences (all)	114	0	0

<b>Non-serious adverse events</b>	Cohort B: SC Herceptin by Single- Use Injection Device (SID)		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	576 / 709 (81.24%)		
Investigations			
Ejection fraction decreased			
subjects affected / exposed	36 / 709 (5.08%)		
occurrences (all)	43		
Injury, poisoning and procedural complications			
Radiation skin injury			
subjects affected / exposed	68 / 709 (9.59%)		
occurrences (all)	78		
Vascular disorders			
Hot flush			
subjects affected / exposed	72 / 709 (10.16%)		
occurrences (all)	77		
Hypertension			
subjects affected / exposed	35 / 709 (4.94%)		
occurrences (all)	50		
Nervous system disorders			

Headache			
subjects affected / exposed	73 / 709 (10.30%)		
occurrences (all)	89		
Neuropathy peripheral			
subjects affected / exposed	56 / 709 (7.90%)		
occurrences (all)	65		
Paraesthesia			
subjects affected / exposed	70 / 709 (9.87%)		
occurrences (all)	87		
Dizziness			
subjects affected / exposed	32 / 709 (4.51%)		
occurrences (all)	35		
Peripheral sensory neuropathy			
subjects affected / exposed	21 / 709 (2.96%)		
occurrences (all)	25		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	132 / 709 (18.62%)		
occurrences (all)	168		
Asthenia			
subjects affected / exposed	85 / 709 (11.99%)		
occurrences (all)	107		
Pyrexia			
subjects affected / exposed	55 / 709 (7.76%)		
occurrences (all)	67		
Oedema peripheral			
subjects affected / exposed	45 / 709 (6.35%)		
occurrences (all)	49		
Injection site erythema			
subjects affected / exposed	52 / 709 (7.33%)		
occurrences (all)	124		
Mucosal inflammation			
subjects affected / exposed	53 / 709 (7.48%)		
occurrences (all)	64		
Injection site pain			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Injection site reaction</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Pain</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>37 / 709 (5.22%)</p> <p>107</p> <p>36 / 709 (5.08%)</p> <p>58</p> <p>36 / 709 (5.08%)</p> <p>41</p>		
<p>Blood and lymphatic system disorders</p> <p>Anaemia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Neutropenia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>43 / 709 (6.06%)</p> <p>53</p> <p>36 / 709 (5.08%)</p> <p>45</p>		
<p>Gastrointestinal disorders</p> <p>Diarrhoea</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Nausea</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Constipation</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Vomiting</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Stomatitis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Abdominal pain</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Dyspepsia</p>	<p>130 / 709 (18.34%)</p> <p>184</p> <p>102 / 709 (14.39%)</p> <p>133</p> <p>62 / 709 (8.74%)</p> <p>73</p> <p>38 / 709 (5.36%)</p> <p>45</p> <p>42 / 709 (5.92%)</p> <p>47</p> <p>36 / 709 (5.08%)</p> <p>45</p>		



subjects affected / exposed occurrences (all)	44 / 709 (6.21%) 50		
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)  Dyspnoea subjects affected / exposed occurrences (all)  Epistaxis subjects affected / exposed occurrences (all)	56 / 709 (7.90%) 59  47 / 709 (6.63%) 49  30 / 709 (4.23%) 35		
Skin and subcutaneous tissue disorders Rash subjects affected / exposed occurrences (all)  Erythema subjects affected / exposed occurrences (all)  Alopecia subjects affected / exposed occurrences (all)  Pruritus subjects affected / exposed occurrences (all)	74 / 709 (10.44%) 113  74 / 709 (10.44%) 86  49 / 709 (6.91%) 50  35 / 709 (4.94%) 40		
Psychiatric disorders Insomnia subjects affected / exposed occurrences (all)	50 / 709 (7.05%) 52		
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)  Myalgia subjects affected / exposed occurrences (all)	133 / 709 (18.76%) 160  84 / 709 (11.85%) 107		

Pain in extremity subjects affected / exposed occurrences (all)	49 / 709 (6.91%) 63		
Back pain subjects affected / exposed occurrences (all)	42 / 709 (5.92%) 44		
Musculoskeletal pain subjects affected / exposed occurrences (all)	36 / 709 (5.08%) 40		
Bone pain subjects affected / exposed occurrences (all)	40 / 709 (5.64%) 53		
Infections and infestations			
Nasopharyngitis subjects affected / exposed occurrences (all)	58 / 709 (8.18%) 79		
Upper respiratory tract infection subjects affected / exposed occurrences (all)	21 / 709 (2.96%) 25		
Urinary tract infection subjects affected / exposed occurrences (all)	32 / 709 (4.51%) 43		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
19 November 2012	The amendment allowed subjects to be treated with SC Herceptin according to indication and to allow a sub-population of subjects to be enrolled to provide complementary safety data for regulatory purposes. The duration of treatment-free follow-up was extended from a minimum of 2 years to a minimum of 5 years, and the AE reporting timeframe was revised.
18 March 2013	The protocol was amended to clarify the timeframe for AE reporting as well as the definition of "treatment period". Subjects were also allowed the opportunity to self-administer SC Herceptin via SID at the discretion and supervision of the HCP.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported